As the Australian share market shows resilience with a +0.4% advance amidst global uncertainties, particularly contrasting Wall Street’s downturn, investors are keenly observing how local factors such as potential interest rate changes influence trading sentiment. In this environment, companies with high insider ownership often attract attention for their perceived alignment of interests between management and shareholders, making them notable candidates for those seeking growth opportunities on the ASX.
|
Name |
Insider Ownership |
Earnings Growth |
|
Torque Metals (ASX:TOR) |
18.3% |
94.2% |
|
Titomic (ASX:TTT) |
14.7% |
82.9% |
|
Starpharma Holdings (ASX:SPL) |
15.6% |
91.8% |
|
SKS Technologies Group (ASX:SKS) |
28.2% |
31.7% |
|
Magnetic Resources (ASX:MAU) |
33.6% |
124.2% |
|
Image Resources (ASX:IMA) |
20.4% |
148.6% |
|
Forrestania Resources (ASX:FRS) |
32.4% |
102.3% |
|
Echo IQ (ASX:EIQ) |
19.7% |
108.7% |
|
Austral Resources Australia (ASX:AR1) |
19.4% |
38.8% |
|
Adveritas (ASX:AV1) |
17.9% |
109.9% |
Let’s dive into some prime choices out of the screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Aurelia Metals Limited is involved in the exploration and production of mineral properties in Australia, with a market cap of A$431.82 million.
Operations: The company generates revenue from its mineral exploration and production activities in Australia.
Insider Ownership: 25.9%
Earnings Growth Forecast: 23.8% p.a.
Aurelia Metals shows promising growth potential with earnings forecasted to grow significantly at 23.8% annually, outpacing the Australian market. Its recent half-year results reflect a strong performance with sales reaching A$206.87 million and net income of A$22.59 million, indicating robust operational momentum. While trading well below its estimated fair value and expected to rise by 63.9%, insider ownership remains stable without substantial recent buying or selling activity, suggesting confidence in long-term prospects.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Regis Healthcare Limited provides residential aged care services in Australia and has a market cap of A$2.06 billion.
Operations: The company generates revenue of A$1.26 billion from residential aged care, home care, and retirement living services in Australia.
Insider Ownership: 38.6%
Earnings Growth Forecast: 22.7% p.a.
Regis Healthcare is positioned for growth, with earnings expected to rise by 22.7% annually, surpassing the Australian market’s forecast. The company reported A$744.7 million in revenue for the recent half-year, though net income declined to A$13.44 million from A$24.4 million a year prior. Insider activity shows more buying than selling recently, albeit not in large volumes, indicating confidence amid strategic acquisitions and greenfield development plans supported by a robust balance sheet and undrawn debt facilities.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals, with a market cap of A$5.05 billion.
Operations: The company’s revenue is derived from three primary segments: Therapeutics ($9.27 million), Precision Medicine ($621.93 million), and Manufacturing Solutions ($245.11 million).
Insider Ownership: 14.9%
Earnings Growth Forecast: 45.5% p.a.
Telix Pharmaceuticals is poised for growth, with revenue projected to increase by 14% annually, outpacing the Australian market. Despite a net loss of US$7.13 million in 2025, strategic collaborations, such as with Regeneron Pharmaceuticals and advancements in glioblastoma treatments like TLX101-Tx entering Phase 3 trials, bolster its potential. The company’s strong insider ownership could reflect confidence in its innovative pipeline and expanding global presence through new regulatory approvals and strategic alliances.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include ASX:AMI ASX:REG and ASX:TLX.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
















